Quality Issues for Multiregional Clinical-Trial Materials - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quality Issues for Multiregional Clinical-Trial Materials
The authors examine risk management relating to the quality issues of clinical-trial materials and discuss areas that would benefit from additional consideration and harmonization.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 124-132

Stability studies

Clinical-trial materials are by their nature experimental items that undergo evolution as the potential drug candidate progress through clinical development. Because they are experimental, there is a certain amount of risk originating from the relative lack of information regarding functional performance and how critical dosage form attributes might be changing over time.

From the standpoint of the formulation scientist, two principal risk-management goals need to be achieved during a clinical trial. First, the safety of participating study volunteers must be ensured by minimizing controllable safety threats. Second, if an investigational compound fails to meet clinical-study objectives, whether for efficacy or toxicological reasons, it should be from a intrinsic outcome of the compound itself and not because of a failure in performance of the dosage form.


Table I. Comparison of various features: clinical investigation at different stages and extent of control over distributed trial supplies.
The risk-management exercise is driven by the general interest in moving to human trials as soon as possible to validate a proof of concept for pharmacological activity and determine if a particular compound is worthy of further consideration. As a consequence, early-development timelines typically are short, meaning that only a limited amount of information is available on dosage-form performance as a function of time and storage conditions. The uncertainty from the lack of stability data is partially balanced by the fact that early clinical trials are short in duration, involve a small numbers of subjects, and have a high level of control over the storage and handling of the clinical-trial materials. As illustrated in Table I, when a compound moves to the next stages of clinical development, the amount of data collected on performance increases, thereby resulting in reduced uncertainty in some respects. In parallel, the length of trial, the numbers of subjects involved, and the diminished control over the test articles also are increasing, thereby somewhat offsetting the increased data set.

The statistical tools and evaluation criteria for stability data collected at the end stages of development, especially in support of marketing authorizations, are well developed. They primarily consist of linear least-squares techniques with hypothesis testing on slopes to determine whether a significant change over time is occurring for critical parameters. Poolability of slopes and intercepts is used to determine if product characteristics are reproducible between batches.

These tools are less useful at the earlier stages in development because of the limited duration of available stability data. Formulations typically are undergoing rapid evolution and are produced in very limited quantities, so homogeneity across batches cannot be ensured. Opportunities to use neural networks in cases such as these have been explored but have not been widely implemented (18). Other multivariate techniques, such as cluster analysis or pattern-recognition methods, which capitalize on previous work with related compounds or formulations would be worthy of further exploration.

Conclusion

There is considerable opportunity to improve drug development without compromising the strong safeguards that mitigate risk to subjects in clinical trials, including, areas that would benefit from additional consideration and harmonization. Although broad regulatory requirements exist for materials going into clinical trials, more defined best practices that reflect the stage of development and risk-management practices would be a benefit to industry, regulators, and patients. The vetting of such best practices should be through an open process that involves these same stakeholders. To be most effective, best practices should be sufficiently detailed yet flexible and subject to continuous improvement. The current philosophy of regulatory agencies has been to set a general framework for regulatory expectations through formal guidance documents but not to supply the level of detailed implied herein. As a result, there is the belief that drug developers either individually or collectively justify approaches that satisfy these general expectations. Further clarification for industrywide best practices, however, would be tremendously beneficial. The vehicle for establishing these best practices needs to be carefully considered and can include pharmacopeial standards, publications by industry consortia, or other standard-setting bodies.

Dennis Sandell* is director of S5 Consulting, Järnåkravägen 3, SE-222 25, Lund Sweden, tel. + 46 46 150703,
. Terrence Tougas is a highly distinguished research fellow, Dennis O'Connor is clinical supplies officer, and Steve Horhota is a highly distinguished research fellow, all with Boehringer Ingehelheim.

*To whom correspondence should be directed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here